Translational Development Acquisition Corp. (TDAC)
Translational Development Acquisition will go public soon, but the exact IPO date is still unknown.
IPO Price
$10.00
Shares Offered
15,000,000
Deal Size
$150.00M
Company Description
Translational Development Acquisition Corp. is a newly organized blank check company formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination.
We intend to initially concentrate on target businesses making a positive contribution to human health in the healthcare or healthcare related industries.
In particular, we will target North American or European companies in the life sciences and biotechnology sectors where our management has extensive investment experience.
We intend to focus on target businesses with valuations of $300 to $500 million or more and that have the potential to be $1 billion or more market capitalization companies.
Translational Development Acquisition Corp.
| Country | United States |
| Founded | 2022 |
| Industry | Shell Companies |
| Sector | Financials |
| CEO | Michael B. Hoffman |
Contact Details
Address: 1270 Avenue of the Americas, 24th Floor New York, NY 10020 United States | |
| Phone | (917) 979-3072 |
Stock Details
| Ticker Symbol | TDAC |
| Exchange | NASDAQ |
| Reporting Currency | USD |
| IPO Price | $10.00 |
| CIK Code | 0001926599 |
| SIC Code | 6770 |
Key Executives
| Name | Position |
|---|---|
| Michael B. Hoffman | Chief Executive Officer, Director |
| Avanindra C. Das | Chief Financial Officer |
| John M. Glazer | Director Nominee |
| E. Premkumar Reddy | Director Nominee |
| Curtis T. Keith | Director Nominee |
| Maria L. Maccecchini | Director Nominee |
| Susan P. Kennedy | Director Nominee |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 26, 2022 | S-1 | General form for registration of securities under the Securities Act of 1933 |
| Jun 13, 2022 | DRS | [Cover] Draft Registration Statement |